Trial · NCT04727476
The Use of Lisdexamfetamine for Children Aged 7-13 With Attention Deficit Disorders
NCT04727476, Unknown, Aarhus University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Use of Lisdexamfetamine for Children Aged 7-13 With Attention Deficit Disorders. Trials, record NCT04727476. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04727476
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Use of Lisdexamfetamine for Children Aged 7-13 With Attention Deficit Disorders
- NCT number
- NCT04727476
- Status
- Unknown
- Enrollment
- 413 participants, actual
- Lead sponsor
- Aarhus University Hospital
- Conditions
- Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, Hyperkinetic Disorder
- Interventions
- Lisdexamfetamine
- First posted
- 2021-01-27
- Last updated
- 2021-08-11
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Lisdexamfetamine as first, second and third choice of treatment (+/- dexamfetamine as supplementary treatment). | Prescription of lisdexamfetamine sometime during the period from 1 April 2013 until 5 November 2019. | Number of patients receiving lisdexamfetamine as first, second and third choice (+/- dexamfetamine as supplementary treatment). |
| Secondary | Duration of treatment. | ADHD treatment prescribed in the period from 1 April 2013 to 5 November 2019. | Duration of treatment of first, second and third choice of treatment (days/months). |
| Secondary | ADHD symptoms. | At baseline and at the most stable dosage of a drug from prescription to discontinuation (first, second and third choice of treatment) in the period from 1 April to 5 November 2019.. | ADHD symptoms according to DuPaul's ADHD rating scale. The rating scale is sent out to parents and schools before each consultation every 6 months. |
| Secondary | Adverse effects. | All adverse effects registered during medical treatment from prescription to discontinuation of a drug (first, second and third choice of treatment) in the period from 1 April 2013 to 5 November 2019.to . | Adverse effects of the medical treatments registered by clinicians in the patient journals. Adverse effects will be classified by System Organ Class (SOC) and Preferred Term (PT) level according to the Medical Dictionary for Regulatory Activities (MedDRA) (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use 2014. |
| Secondary | Reasons for discontinuing medical treatment. | At the time point (date) when a medical treatment is discontinued in the period from 1 April 2013 to 5 November 2019.. | Reasons for discontinuing medical treatment (first, second and third choice of treatment) as registered by clinicians in the patient journals. Reasons will be categorised as being due to one or more of the following; lack of effect, adverse effects, patient/parental request, non-compliance, wish for more optimal day coverage. |
| Secondary | Maximal dosage. | The maximal dosage prescribed of a drug from first prescription to discontinuation (first, second and third choice of treatment) in the period from 1 April to 5 November 2019. | The maximal dosage of the prescribed drug from prescription to discontinuation of a medical treatment (first, second and third choice of treatment). |
| Secondary | Final dosage. | Either the dosage immediately before switching medication or at the end of the study period (5 November 2019). | Final dosage of a treatment. |
| Secondary | Characteristics of patients continuing with lisdexamfetamine treatment. | In the period from 1 April 2013 to 5 November 2019 | Characteristics of patient continuing treatment with lisdexamfetamine regarding gender, age, diagnosis, ADHD symptoms at baseline, comorbidities, and adverse effect profile. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04727476
GET https://conductscience.org/api/trials/v1/NCT04727476/registered